3 studies on JMR-132 curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab currently curates 3 dated studies on JMR-132. The source summaries below describe published research; they do not establish product quality, safety, or clinical suitability.
**Tumors that express functional `p21/waf1` may be selectively vulnerable to GHRH antagonist therapy** — and conversely, cancers with silenced or mutated `p21` are likely non-responders. This mechanistic clarity could…
**GHRH antagonism via JMR-132 may represent a receptor-status-agnostic therapeutic axis in breast cancer**, addressing a major clinical gap: ER-negative tumors have few hormone-based treatment options. The dual activi…
**GHRH antagonists like JMR-132 may represent a mechanistically distinct antiproliferative strategy** for ovarian cancers expressing SV1 of the GHRH receptor, targeting the `EGFR-Akt` axis without being a direct EGFR …
Free, no account — handy when you're working with JMR-132.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$14 monthly or $88/year
Create an account